Education in lung cancer management for doctors in community practices is of high priority for IASLC. I am proud to tell that IASLC has recently made a joint project partnership with American College of Chest Physicians (ACCP) to develop educational “class room” programs in diagnosis and management of patients with lung cancer, which will include programs in the US and Europe. IASLC is very proud of this collaborative effort, and the first summit will be held in the US this fall.
Personalized medicine is a popular term but yet its success doesn’t come easy. Over the past decade we had successfully established EGFR mutation and ALK mutation as the prime target for personalized medicine. The key ingredients to successful formula of personalize therapy for lung cancer would include driver oncogene, biomarker and established efficacy in the biomarker-selected population ( and lack of such in the biomarker-negative population).
May 28, 2014 at 6 pm CEST (Rome) - Topic Chemotherapy for Advanced NSCLC: State-of-the-Art in 2014 - The European Perspective
June 23, 2014 at 8 pm EDT - Topic: Biomarkers and Personalized Medicine for Patients with Lung Cancer
The International Association for the Study of Lung Cancer (IASLC) is disappointed in the recommendations made by the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) to not support Medicare coverage of low-dose computed tomography (LDCT) screening of patients at high risk for lung cancer.